Details of the Drug Formulations

General Information of Drug (ID: DMOB58Q)

Drug Name
MK-8228 Drug Info
Synonyms Letermovir
Indication
Disease Entry ICD 11 Status REF
Cytomegalovirus Disease 1D82 Approved [1]
Cytomegalovirus infection 1D82 Phase 3 [2]
Cross-matching ID
PubChem CID
45138674
CAS Number
917389-32-3
TTD ID
D0G8PA
VARIDT ID
DR00621
INTEDE ID
DR0928
ACDINA ID
D00355

Full List of Drug Formulations Containing This Drug

Letermovir 480 mg tablet
Company Formulation ID FDA Description
Merck Sharp & Dohme F11371 Lactose monohydrate; Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Titanium dioxide; Triacetin; Croscarmellose sodium; Silicon dioxide; Carnauba wax; Hypromellose 2910 (15 mpa.s); Hypromellose 2910 (6 mpa.s); Microcrystalline cellulose; Povidone k25
------------------------------------------------------------------------------------
Letermovir 240 mg tablet
Company Formulation ID FDA Description
Merck Sharp & Dohme F11370 Lactose monohydrate; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Triacetin; Croscarmellose sodium; Silicon dioxide; Carnauba wax; Hypromellose 2910 (15 mpa.s); Hypromellose 2910 (6 mpa.s); Microcrystalline cellulose; Povidone k25
------------------------------------------------------------------------------------

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93.